OAM
PLSE icon

Oxford Asset Management’s Pulse Biosciences PLSE Stock Holding History

Oxford Asset Management’s Portfolio PLSE Stock Details PLSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-8,969
Closed -$310K – 1661
2017
Q2 		$310K Buy
+8,969
New +$247K 0.01% 1251

Other funds holding PLSE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HCS
Harvest Capital Strategies San Francisco, California $73.7M AUM 7.47% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
TF
TIAA FSB Jacksonville, Florida $27.6B AUM 14.26% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Oxford Asset Management's PLSE Position: Q3 2017 in Review

Oxford Asset Management sold out of Pulse Biosciences (PLSE) in Q3 2017, closing a stake of 8,969 shares — an estimated $310K sold.

Oxford Asset Management first reported a position in PLSE in Q2 2017 and held it in 1 quarter. The position peaked at $310K in Q2 2017. 43 funds tracked by Wall St. Rank hold PLSE as of Q3 2017.

  • Oxford Asset Management reported no remaining Pulse Biosciences position as of Q3 2017 after selling out during the quarter.
  • Oxford Asset Management sold 8,969 Pulse Biosciences shares in Q3 2017, an estimated $310K.
  • Oxford Asset Management first reported a position in Pulse Biosciences in Q2 2017 and held it in 1 quarter.
  • Oxford Asset Management's Pulse Biosciences position peaked at $310K in Q2 2017.
  • 43 funds tracked by Wall St. Rank held Pulse Biosciences as of Q3 2017.

Based on Oxford Asset Management's 13F filing for Q3 2017, filed 13 Nov 2017.